Abbott India Ltd - Stock Valuation and Financial Performance

BSE: 500488 | NSE: ABBOTINDIA | Pharmaceuticals & Drugs | Mid Cap

Abbott India Share Price

27,197.40 206.90 0.77%
as on 12-Apr'24 10:20

DeciZen - make an informed investing decision on Abbott India

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

Abbott India stock performance -

mw4me loader
P/E Ratio (SA):
49.09
Market Cap:
56,238 Cr.
52-wk low:
20,594.3
52-wk high:
29,628.2

Is Abbott India Ltd an attractive stock to invest in?

1. Is Abbott India Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Abbott India Ltd is a good quality company.

2. Is Abbott India Ltd undervalued or overvalued?

The key valuation ratios of Abbott India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Abbott India Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Abbott India Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Abbott India:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Abbott India Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 27.3%26.8%24.3%21.8%24.4%24.2%27.3%28.1%30%32.1%-
Value Creation
Index
1.01.00.80.60.80.81.41.51.71.9-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 1,8212,2892,6152,9033,2993,6794,0934,3104,9135,3495,753
Sales YoY Gr.-25.7%14.2%11%13.6%11.5%11.3%5.3%14%8.9%-
Adj EPS 73.8108.7121.3131.9175.6210.2281.9326.4377448.1539.1
YoY Gr.-47.2%11.7%8.7%33.2%19.7%34.1%15.8%15.5%18.9%-
BVPS (₹) 296.6441.2562.7646.4786.8932.21,127.51,203.71,306.21,480.51,609.4
Adj Net
Profit
1572312582803734475996948019521,146
Cash Flow from Ops. 124215249307153499626727948893-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 12.7%10.2%9.3%8.9%
Adj EPS 22.2%20.6%16.7%18.9%
BVPS19.6%13.5%9.5%13.3%
Share Price 31.3% 29.7% 22.1% 21%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
27.326.824.221.724.224.12727.629.631.734.9
Op. Profit
Mgn %
12.113.814.113.81616.518.721.422.122.624.4
Net Profit
Mgn %
8.610.19.99.711.312.114.616.116.317.819.9
Debt to
Equity
0000000000-
Working Cap
Days
1632191469311611998918511895
Cash Conv.
Cycle
46443219179-2-5-13-2156

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 34.90%

Sales growth has been subdued in last 3 years 9.33%

Sales growth is not so good in last 4 quarters at 9.37%

Latest Financials - Abbott India Ltd.

Standalone Consolidated
TTM EPS (₹) 539.1 0
TTM Sales (₹ Cr.) 5,753 0
BVPS (₹.) 1,609.4 0
Reserves (₹ Cr.) 3,399 116
P/BV 16.44 0.00
PE 49.09 0.00
From the Market
52 Week Low / High (₹) 20594.25 / 29628.15
All Time Low / High (₹) 145.00 / 29628.15
Market Cap (₹ Cr.) 56,238
Equity (₹ Cr.) 21.3
Face Value (₹) 10
Industry PE 48

Management X-Ray of Abbott India:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Abbott India

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales2,2762,2892,6152,9033,2993,6794,0934,3104,9135,349
Operating Expenses 2,0091,9782,2512,5082,7753,0753,3373,3913,8324,143
Manufacturing Costs27181921222732293637
Material Costs1,2991,3141,4941,7151,9002,0892,3162,3912,6572,975
Employee Cost 300305341345394436476493579564
Other Costs 382341396427459523513478559568
Operating Profit 2673113643955236047569191,0821,205
Operating Profit Margin (%) 11.7%13.6%13.9%13.6%15.9%16.4%18.5%21.3%22.0%22.5%
Other Income 494851601181141158383154
Interest 0132429181916
Depreciation 22151416161760586670
Exceptional Items 0000000000
Profit Before Tax 2953443984366216998039261,0801,274
Tax 96115143160220249210235281324
Profit After Tax 198229255277401450593691799949
PAT Margin (%) 8.7%10.0%9.8%9.5%12.2%12.2%14.5%16.0%16.3%17.8%
Adjusted EPS (₹)93.4107.8120.1130.2188.8211.9279.0325.0375.9446.8
Dividend Payout Ratio (%)25%29%29%31%29%31%90%85%73%73%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 7889381,1961,3741,6721,9812,3962,5582,7763,146
Share Capital 21212121212121212121
Reserves 7679161,1741,3521,6511,9602,3752,5372,7543,125
Minority Interest0000000000
Debt0000000000
Long Term Debt0000000000
Short Term Debt0000000000
Trade Payables136194230475481664658763889892
Others Liabilities 9591,073181205249283479502542501
Total Liabilities 1,8832,2041,6072,0532,4022,9283,5323,8234,2074,539

Fixed Assets

Gross Block209216123140124165345341426455
Accumulated Depreciation111120143043607590155218
Net Fixed Assets989610811081105270251271237
CWIP 1436212114
Investments 0000000000
Inventories359384370501585607527718688649
Trade Receivables109129145176263276318250288317
Cash Equivalents 4636448391,0911,0311,6842,1972,4092,7491,937
Others Assets8539471411704382552181942101,395
Total Assets 1,8832,2041,6072,0532,4022,9283,5323,8234,2074,539

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 155215249307153499626727948893
PBT 2953443984366216998039261,0801,274
Adjustment -1-37-24-37-77-77-172523-63
Changes in Working Capital -28232267-187134701113423
Tax Paid -110-116-147-159-205-257-229-235-289-341
Cash Flow From Investing Activity -144-187-77-155-215-257-401-72-396-148
Capex -4-16-23-21274-16-23-44-34
Net Investments -172-211-105-189-105-554-506-135-421-216
Others 32405055-1372931208669102
Cash Flow From Financing Activity -42-58-80-90-102-143-217-582-637-639
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 00-100-20-1-10
Dividend Paid -42-49-66-74-85-117-138-531-584-584
Others 0-9-13-15-17-24-78-50-52-54
Net Cash Flow -31-309162-16599873-86107
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)27.6626.5423.9321.5426.3524.6627.0927.8929.9532.07
ROCE (%)41.0739.9837.5533.9640.6137.8836.5437.5240.5342.93
Asset Turnover Ratio1.511.131.391.611.481.381.271.221.251.26
PAT to CFO Conversion(x)0.780.940.981.110.381.111.061.051.190.94
Working Capital Days
Receivable Days20191920242726232020
Inventory Days49595254605951515144
Payable Days3346527592100104108113109

Abbott India Ltd Stock News

Abbott India Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Abbott India on 12-Apr-2024 10:20 is ₹27,197.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Apr-2024 10:20 the market cap of Abbott India stood at ₹56,238.
The latest P/E ratio of Abbott India as of 12-Apr-2024 10:20 is 49.09.
The latest P/B ratio of Abbott India as of 12-Apr-2024 10:20 is 16.44.
The 52-week high of Abbott India is ₹29,628.2 and the 52-week low is ₹20,594.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Abbott India is ₹5,753 ( Cr.) .

About Abbott India Ltd

Since 1910, Abbott has been dedicated to helping people in India live healthier lives through a diverse range of science-based nutritional products, diagnostic tools, branded generic pharmaceuticals, and diabetes and vascular devices. Abbott India Limited is a public limited company domiciled and incorporated in India under the provisions of the then Companies Act, 1913. The company is listed and traded on the Bombay Stock Exchange. It is traded on the National Stock Exchange under the ‘permitted category’.

Abbott India, a publicly listed company and a subsidiary of Abbott Laboratories, takes pride in offering high-quality trusted medicines in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders and primary care.

One of India's fastest-growing pharmaceutical companies, Abbott India Limited is part of Abbott's global pharmaceutical business in India. It has expertise across product development, manufacturing, sales and customer service and dedicated to providing high-quality, reliable products with the expert clinical support customers need.

Abbott India provides quality healthcare through a mix of global and local products for people in India. Its in-house development and medical teams undertake product and clinical development tailored to the unique needs of the Indian market. Its employees work to produce high-quality, high-volume formulations using cost efficient processes. And, its trained personnel are dedicated to ensuring compliance with international quality standards.

Business area of the company

The company is one of the leading multinational pharmaceutical companies in India and operates with owned manufacturing units and various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily within India.

Products and Services offered by the company

  • Cardiovascular- Keeping heart healthy with breakthrough medical technologies.
  • Diabetes- Helping people with diabetes enjoy healthier, active lives.
  • Diagnostics- Bringing accurate, timely information to better manage health.
  • Neuromodulation- Innovative solutions to movement disorders and chronic pain treatment.
  • Nutrition- Nourishing body at every stage of life.
  • Pharmaceuticals- Helping people get and stay healthy with quality medicines.

Awards

  • 2013- Awarded Frost & Sullivan ‘MNC Pharmaceutical Company of the Year’ for the third consecutive year.
  • 2014 -Abbott, one of the largest diversified global healthcare companies and the number one pharmaceutical company in India, in partnership with the Indian Thyroid Society (ITS), announced the launch of a thyroid awareness initiative in Uttar Pradesh and Uttarakhand.            
  • 2014- Abbott was awarded the prestigious Golden Peacock Innovation Management Award at the 8th International Conference on Corporate Social Responsibility held in Bangalore. 
  • 2018- ‘Best Companies to Work’
  • 2018- Best Use Of Technology for Training Excellence in The Production of Learning Content
  • 2019- Company of the Year (Abbott India)
  • 2019- Brand of the Year (Thyronorm) by AWACS
  • 2019- Excellence in Content Development for e-detailing training - Rajni ka iPad by National Awards for Training and Development
  • 2019- Gold for Best Content in a B-2-B Marketing Campaign - Immersive storytelling (using AR) for doctors at the India Content Leadership Award
  • 2019- Outstanding patient support for Gutfit by CMO Asia
  • 2019- Gold Award for Best Use of Market Research - PR MomvsFlu by Global Customer Engagement.
  • 2020- Best Financial Content For The 75th Annual Report at India Content Leadership Awards
  • 2020- Cremaffin Plus - Brand Excellence Award in Pharmaceutical sector at ABP Brand Excellence Award.
  • 2020- GUTFIT - Best Patient Education Project Award at ZEE Business’s - National Healthcare Leadership Awards
  • 2020- UDILIV - Brand Of The Year -Bronz at the AWACS Award - Acute category
  • 2020- Best Patient-Centric Design At Pharmapack Europe - G’DoCon - Granule Dosing Concept of CREON SD 
  • 2020- Best Digital Media Content by a Healthcare Enterprise for Mother Against Influenza (MAI) at the India Content Leadership Awards

History and Milestones

Dr. Abbott’s spirit of entrepreneurship, innovation and caring lives on in culture, business and contributions to medical science. Read below for historical moments that highlights the pursuit of the extraordinary throughout the years.

  • 1888- Production of ‘alkaloidal’ medicine granules by Dr. Wallace C. Abbott, a 30-year-old practicing physician, begins in the rear of his People’s Drug Store in Chicago. Remedies contain the active ingredients of plants and herbs. First-year total sales reach $2,000.
  • 1894- Incorporated as the Abbott Alkaloidal Company. Abbott is a medical publisher as well as a manufacturer.
  • 1907- Expansion outside the United States for the first time with an office in London, England.
  • 1916- Production of first synthetic medicine, Chlorazene, a breakthrough antiseptic developed by British chemist Dr. Henry Dakin to treat wounded soldiers in World War I.
  • 1922- Development of Butyn by scientists Dr. Ernest Volwiler and Dr. Roger Adams, the first in a long line of breakthrough anesthetics to come from company.
  • 1929- Initial public offering provides shares for the first time in the year of the stock market crash that began the Great Depression. While the timing seems inauspicious, stock grows in value from that first day-and approximately 10,000 times over so far.
  • 1932- Expansion continues even at the height of the Great Depression thanks to leadership in new fields such as vitamins and intravenous solutions. “Few of the leading industrial organizations of the country,” notes Nation’s Commercemagazine, “can show a sounder record for the past year than the Abbott Laboratories.”
  • 1935- Introduction of Pentothal, which will be the world’s leading anesthetic for years to come and win inventors, Dr. Volwiler and Dr. Donalee Tabern, induction into the U.S. National Inventors Hall of Fame.
  • 1942- Abbott joins a consortium of pharmaceutical makers, at the behest of the U.S. Government, to ramp up production of penicillin for wartime use. Together it increase production more than 20,000%.
  • 1959- Adoption of Abbott “A” logo, a classic of industrial design that remains the cornerstone of visual identity to this day.
  • 1960- Reinvention in the 1960s under? President George? Cain is ?featured in the 2001 ?best-seller, Good to? Great- Why Some? Companies Make the ?Leap... and Others Don’t. Author Jim Collins? chose as one of 11 companies, out of 1,435, that had the product, service, organizational and people quality to engender truly great performance.
  • 1964- Acquisition of M&R Dietetics, with its popular baby formula, Similac, makes a leader in nutrition.
  • 1972- Introduction of the ABA-100 blood chemistry analyzer as well as Ausria, a breakthrough radioimmunoassay test for detecting serum hepatitis. This marks the beginning of modern diagnostics business, in which it quickly became a world leader.
  • 1985- Approval of the first licensed test to identify the HIV virus in blood, helping to secure the safety of the blood supply. This is one of greatest achievements and the first significant medical victory against what had, until then, seemed an unstoppable threat.
  • 1998- Introduction of Glucerna, a group of cereals, health shakes and snack bars formulated specifically for diabetics and others with dietary restrictions.
  • 2002- FDA approval of Humira, the first fully-human monoclonal antibody drug. It will go on to become the world's leading pharmaceutical product.
  • 2006- Launch of the Xience V drug-eluting stent. It goes on to become the market leader.
  • 2010- Continue its focus on globalism as it becomes the largest pharmaceutical company in India, the world’s second-largest country by population.
  • 2013- Beginning of a new era for Abbott, as a more global, consumer-focused company than ever before, it created a new, Fortune 200 corporation, AbbVie, from former proprietary pharmaceutical business.
  • 2014- Abbott establishes a strong new expression of its corporate identity with “Life. To The Fullest.” The company promotes its identity more vigorously than ever before, advertising to consumer audiences around the world and becoming the sponsor of the Abbott World Marathon Majors, a series of the world’s most prominent races.
  • 2014- With the launch of its cutting-edge continuous glucose monitoring system, FreeStyle Libre, Abbott revolutionizes diabetes care by eliminating the need for routine fingersticks.1
  • 2016- Abbott launches the first systems in its Alinity series, a family of diagnostics and informatics systems that represent a major leap forward in terms of reliability, cost, capacity, space efficiency, and ease of use. It are creating the future of diagnostic labs.
  • 2017- In its largest acquisition ever, Abbott acquires St. Jude Medical, adding breakthrough inventions and extensive expertise across the areas of cardiovascular and neuromodulation. Abbott now competes in nearly every area of cardiovascular health and holds the No. 1 or 2 positions in a variety of large, high-growth markets.
  • 2017- Abbott acquires Alere Inc., making Abbott the leader in point-of-care diagnostic technology filling out its array of diagnostics technologies. Abbott now holds the No. 1 position in rapid testing for cardiometabolic disease, infectious disease and in toxicology.
  • 2018- For women health, company has launched Estrabet Gel, Doxstem, Combinorm Wash, Fertifoid
  • 2019- To help improve diagnosis and treatment of thyroid disorders, bacterial vaginosis and Vitamin D, the company collaborated with Indian Thyroid Society (ITS) and Federation of Obstetric and Gynecological Societies of India (FOGSI) to initiate the Metabolic Women’s Health workshops.
  • 2020- Abbott has launched a new inactivated quadrivalent vaccine for influenza offering protection against four virus strains in India. It is the only 0.5 ml quadrivalent flu vaccine in India that has been approved for use in children below three years.
  • 2020- Abbott has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina. 
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.